Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors
June 07, 2023 07:30 ET
|
Entera Bio Ltd.
JERUSALEM, June 07, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
April 18, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
April 18, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by SanofiMechanism of Action of Tiziana’s first-in-class, only...
Middle East and Africa Human Insulin Market is anticipated to register a CAGR of greater than 4% during 2023 – 2028 - Market Size, Share, Forecasts, and Trends Analysis Report by Mordor Intelligence.
April 05, 2023 09:00 ET
|
Mordor Intelligence
Hyderabad, April 05, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Middle East and Africa Human Insulin Market - (2023 – 2028),” the market is expected to register a...
SHAREHOLDER ALERT: Morris Kandinov Investigating PRVB, MAXR, DNA, and FOX; Shareholders are Encouraged to Contact the Firm
March 29, 2023 09:00 ET
|
Morris Kandinov, LLP
SAN DIEGO, March 29, 2023 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating Provention Bio, Inc., Maxar Technologies Inc., Ginkgo Bioworks Holdings, Inc., and Fox Corporation....
Sanofi, market leader in DTaP pediatric combination vaccines, with 55.4 million doses used in 2021
February 23, 2023 14:00 ET
|
ReportLinker
Lyon, France, Feb. 23, 2023 (GLOBE NEWSWIRE) -- A new study shows that Sanofi is the global market leader among aP-based pediatric combination vaccines with a 74.7% share, leading the move from...
Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
December 07, 2022 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion
November 08, 2022 09:00 ET
|
InSilico Medicine
Abu Dhabi, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research...
Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion
November 08, 2022 09:00 ET
|
InSilico Medicine
New York, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research...
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
August 09, 2022 16:02 ET
|
Revolution Medicines, Inc.
First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development of portfolio of targeted drug candidates for RAS-addicted cancers ...